NASDAQ:TRPX - Nasdaq -
0.317
-0.3 (-48.9%)
The current stock price of TRPX is 0.317 null. In the past month the price decreased by -39.04%. In the past year, price decreased by -87.11%.
Therapix Biosciences Ltd is a specialty pharmaceutical company. It focuses on developing Cannabinoid technologies in treatment of central nervous system disorders. The company's product pipeline consists of THX-TS01, for the treatment of symptoms related to Tourette Syndrome and THX-ULD01, targeted to the high value and under-served market of mild cognitive impairment are in clinical stage. Therapix Biosciences Ltd is based in Tel Aviv, Israel.
Therapix Biosciences Ltd
4 ARIEL SHARON STREET HASHAHAR TOWER 16TH FLOOR
GIVATAYIM L3 5320047
CEO: Gilad Bar-Lev
Phone: 972-3616-7055
The current stock price of TRPX is 0.317 null. The price decreased by -48.9% in the last trading session.
The exchange symbol of Therapix Biosciences Ltd is TRPX and it is listed on the Nasdaq exchange.
TRPX stock is listed on the Nasdaq exchange.
Therapix Biosciences Ltd (TRPX) has a market capitalization of 1.11M null. This makes TRPX a Nano Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TRPX does not pay a dividend.
Therapix Biosciences Ltd (TRPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.04).
ChartMill assigns a technical rating of 2 / 10 to TRPX. When comparing the yearly performance of all stocks, TRPX is a bad performer in the overall market: 96.97% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to TRPX. TRPX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months TRPX reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 57.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -230.26% | ||
ROE | N/A | ||
Debt/Equity | 0 |